The invention relates to the improvement in the control of calcium (Ca) or phosphate (Pi) homeostasis in a human subject who is suffering from chronic kidney disease (CKD) during any of stages 1 to 4 of CKD (as defined in National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 200239(suppl 1):S1-S266.). Improvements in homeostasis will have multiple and numerous benefits to a patient suffering from CKD. The patient will benefit from the prevention of mineral and bone disorders and vascular calcification associated with CKD (the cardiovascular events are the leading causes of premature death in patients suffering from CKD). The improvement in the control of Ca and Pi homeostasis is achieved through the administration of parathyroid hormone (PTH) or a derivative to the patient
